Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.

摘要

Glioblastoma (GBM) is the most common primary malignant brain tumor, and despite recent advances in therapy, the prognosis for patients with GBM remains dismal. The median survival of newly diagnosed GBM patients is 15 months when treated with the current standard of care, which is a multimodality approach that includes maximal surgical resection followed by concurrent chemoradiation and 6 months of adjuvant temozolomide [l]. GBM is one of the most vascular tumors known, and there has been great interest in developing antiangiogenic agents for the treatment of GBM [2]. One of the key regulators of angiogenesis is VEGF, which induces tumor vascularization and facilitates tumor growth [3].